![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » FDA Approves J&J’s Darzalex Faspro Combo for Multiple Myeloma
FDA Approves J&J’s Darzalex Faspro Combo for Multiple Myeloma
![Purple_Approved_Stamp.gif](https://www.fdanews.com/ext/resources/test/Drug-Images4/Purple_Approved_Stamp.gif?t=1576639773&width=430)
Johnson & Johnson’s (J&J) Darzalex Faspro (daratumumab and hyaluronidase-fihj) has received FDA approval when combined with pomalidomide and dexamethasone as a second-line therapy for treating adults with multiple myeloma.
The new indication — Darzalex Faspro’s sixth — was supported by phase 3 results which showed the combination therapy reduced the risk of disease progression or death by 37 percent vs. pomalidomide and dexamethasone alone.
Darzalex Faspro is the only subcutaneous anti-CD38 monoclonal antibody cleared for use with the anti-cancer regimen pomalidomide and dexamethasone.
Upcoming Events
-
21Oct